Consejo Nacional de Salud

394
57 Dann E J, Bar-Shalom R, Tamir A, Haim N, Ben-
Shachar M, Avivi I, Zuckerman T, Kirschbaum M,
Goor O, Libster D, Rowe J M, Epelbaum R, Riskadapted
BEACOPP regimen can reduce the cumulative
dose of chemotherapy for standard and
high-risk Hodgkin lymphoma with no impairment
of outcome, BLOOD, 1 February 2007 _ Volume
109, Number 3 From Www.Bloodjournal.Org By
On November 19, 2008.
58 Kawai K; Miyazaki J; Tsukamoto S; Hinotsu S, Hattori
K, Paclitaxel, Ifosfamide and Cisplatin Regimen
is Feasible for Japanese Patient, Japanese Journal
of Clinical Oncology; Mar 01, 2003; 33, 3; Pro-
Quest Health and Medical Complete, pg. 127
59 Sparano J, Wang M, Martino S, Jones V, Perez E,
Saphner T, Wolff AC, Sledge G W Jr., Wood W
C, Davidson N E, Weekly Paclitaxel in the Adjuvant
Treatment of Breast Cancer, N Engl J Med
2008;358:1663-71.
60 Simpson D, Plosker G L, Paclitaxel As Adjuvant
or Neoadjuvant Therapy in Early Breast Cancer,
Drugs 2004; 64 (16): 1839-1847, Adis International
Limited, Auckland, New Zealand
61 Magi-Galluzzi C, Zhou M, Reuther A M, Dreicer
R, Klein E A, Neoadjuvant Docetaxel Treatment
for Locally Advanced Prostate Cancer A Clinico
pathologic Study, American Cancer Society DOI
10.1002/cncr.22897, Published online 2 August
2007 in Wiley InterScience (www.interscience.
wiley.com).
62 Shelley M, Harrison C, Coles B, Stafforth J, Wilt T,
Mason M. Chemotherapy for hormone-refractory
prostate cancer. Cochrane Database of Systematic
Reviews 2006, Issue 4. Art. No.: CD005247.
DOI: 10.1002/14651858.CD005247.pub2.
63 Eymard JC, Priou F, Zannetti A, Ravaud A, Lepille
D, Kerbrat P, Gomez P, Paule B, Genet D, He´
rait P, Ecstein-Fraı¨sse´ E, Joly F, Randomized
phase II study of docetaxel plus estramustine and
single-agent docetaxel in patients with metastatic
hormone-refractory prostate cancer, Annals of
Oncology 18: 1064–1070, 2007, doi:10.1093/annonc/mdm083,
Published online 13 April 2007
64 Rauschecker HHF, Clarke MJ, Gatzemeier W, Recht
A. Systemic therapy for treating locoregional
recurrence in women with breast cancer. Cochrane
Database of Systematic Reviews 2001, Issue 4.
Art. No.: CD002195. DOI: 10.1002/14651858.
CD002195.
65 Gandhi L, Harding M W, Neubauer M, Langer C
J, Moore M, Ross H J, Johnson B E, Lynch T J, A
Phase II Study of the Safety and Efficacy of the
Multidrug Resistance Inhibitor VX-710 Combined
With Doxorubicin and Vincristine in Patients With
Recurrent Small Cell Lung Cancer, CANCER
March 1, 2007 / Volume 109 / Number 5
66 Shelley M, Harrison C, Coles B, Stafforth J, Wilt T,
Mason M. Chemotherapy for hormone-refractory
prostate cancer. Cochrane Database of Systematic
Reviews 2006, Issue 4. Art. No.: CD005247.
DOI: 10.1002/14651858.CD005247.pub2.
67 Engert, Franklin J, Theodor Eich H, Brillant C,
Sehlen S, Cartoni C, Herrmann R, Pfreundschuh
M, Sieber M, Tesch H, Franke, A, Koch P, de Wit
M, Paulus U, Hasenclever D, Loeffler M, Mu¨ller
R-P, Konrad Mu¨ller-Hermelink H, Du¨hmke H,
Diehl V, Two Cycles of Doxorubicin, Bleomycin,
Vinblastine, and Dacarbazine Plus Extended-
Field Radiotherapy Is Superior to Radiotherapy
Alone in Early Favorable Hodgkin’s Lymphoma:
Final Results of the GHSG HD7 Trial, J Clin Oncol
25:3495-3502